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Abstract
Introduction and hypothesis The aim of this study was to
establish if the management of women with overactive blad-
der (OAB) and patient-reported outcomes differed based on
the findings of urodynamics (UDS).
Methods A prospective, longitudinal observational study con-
ducted in urogynaecology clinics in 22 UK hospitals partici-
pating in the Diagnostic Accuracy of Bladder Ultrasound
Study (BUS). A total of 687 women with OAB symptoms
or urgency-predominant mixed urinary incontinence were re-
cruited into a diagnostic study that used UDS as the reference
standard. Detailed clinical history and International
Consultation on Incontinence OAB Short Form (ICIQ-OAB
sf) questionnaire responses were obtained before the UDS test
was carried out. These questionnaires were subsequently col-
lected at a mean of 7 and 20 months, along with patient global
impression of improvement and details on medical and surgi-
cal treatments. The relationship between UDS diagnosis and
treatment was examined using a multinomial regression mod-
el; logistic and repeated measures regressions were used to
examine other outcomes.
Results We recruited 687 women and the response rate was
69% at 20 months. Treatment subsequent to UDS was highly
associated with diagnosis (p < 0.0001). Women who received
treatment concordant with their UDS findings were more like-
ly to report an improvement in bladder symptoms (57% vs
45%; p = 0.02) and ICIQ-OAB sf scores (0.5 points,
95%CI: 0.1 to 0.9; p = 0.02).
Conclusions Urodynamics influenced treatment decisions
made by clinicians in determining treatment pathways in
women presenting with OAB. Women treated based on
UDS diagnoses appear to have greater reductions in symp-
toms than those who do not.
Keywords Urodynamics . Overactive bladder . Detrusor
overactivity
Introduction
Urinary incontinence can seriously influence the physical,
psychological, and social wellbeing of affected individ-
uals [1]. Urodynamics (UDS) has been considered the test
of choice for lower urinary tract symptoms [2]. The
International Continence Society (ICS) states that the ob-
jective of urodynamic studies is to replicate the patient’s
symptoms whilst making measurements that aim to deter-
mine the underlying cause and in addition evaluate the
related pathophysiological processes [2]. Overactive blad-
der (OAB) is defined as a symptom complex of urinary
urgency (an intense, sudden desire to void) with or with-
out incontinence, usually with increased urinary frequen-
cy, or nocturia, but in the absence of infection or other
proven pathological condition. From UDS testing, multi-
ple diagnoses may be obtained, including detrusor over-
activity (DO), urodynamic stress incontinence (USI), and
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voiding dysfunction (VD) [3, 4]. In women who present
with OAB, 46% do not have a DO diagnosis on UDS [4].
UDS may falsely miss DO or it may not be able to capture
DO at that time point [5]. The National Institute of Health
and Care Excellence Clinical Guidelines on urinary incon-
tinence (NICE CG171) recommends that patients undergo
UDS if they are unresponsive to conservative therapies
[1]. There is a dilemma for clinicians as to whether to
treat women based on their symptoms or their UDS find-
ings [6–8]. Typically in the UK, patients with OAB are
initially offered behavioural therapies and antimuscarinic
drugs. NICE guidelines do not recommend performing
UDS to commence conservative measures. However, bot-
ulinum toxin A can only be offered to women who have
not responded to conservative measures and have proven
DO on UDS [1]. Invasive therapies (botulinum toxin type
A, neuromodulation) can be offered to those with con-
firmed DO.
There are few data on the longitudinal follow-up of women
with urgency or urge-predominant mixed urinary inconti-
nence (MUI) and their response to various medical and surgi-
cal therapies [9]. There is a necessity to establish the role of
UDS and its impact on treatment and patient outcomes in
OAB, as at present its role is unclear.
The aim of this prospective cohort study was to establish if
treatment pathways and outcomes differed following findings
on UDS. More specifically, we wanted to answer the follow-
ing questions:
1. Does the UDS diagnosis affect the management offered?
2. What are the long-term clinical outcomes in this group of
women as measured by a patient global impression of
improvement (PGI-I) question and the International
Consultation on Incontinence overactive bladder short
form (ICIQ-OAB sf) questionnaire?
3. Does the diagnosis by UDS have any prognostic value for
symptoms after 6 and 12 months, i.e. can UDS predict
improvement?
4. Does receiving a concordant medical or surgical treatment
based on urodynamic diagnoses improve women’s
symptoms?
Materials and methods
Women who presented consecutively to the urogynaecology
units in 22 centres in the UK were recruited into a prospective
multicentre study to assess the diagnostic accuracy of bladder
ultrasound (BUS study) in diagnosing detrusor overactivity
(Fig. 1) [10]. The study was conducted based on good clinical
Fig. 1 Study flow diagram. OAB
overactive bladder, DO detrusor
overactivity, USI urodynamic
stress incontinence, QoL quality
of life,
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practice guidelines and ethics approval was obtained
(Nottingham Research Ethics committee REC: 10/H0408/57).
Women over 18 years of age with symptoms of frequency,
urgency, and urge-predominant MUI were approached to par-
ticipate in the study. Following consent, demographics and
detailed clinical history were obtained [10]. Women complet-
ed the ICIQ-OAB sf [11] to determine the extent of the impact
of their symptoms on quality of life (QoL). All women
underwent UDS, using a standardized protocol based on the
good urodynamic practice guidance [2]. Questionnaire book-
lets were sent to women beyond 6 and 12 months post-test.
This included a patient PGI-I [12], the ICIQ-OAB sf question-
naire and questions on medical and surgical treatments re-
ceived by the patients. If no response was received within
4 weeks, reminders were sent. Women who did not respond
within 8 weeks of the initial request were contacted by tele-
phone and questionnaires were completed in a telephone in-
terview with a member of the research team where possible.
With the aim of informing a cohesive analysis, we catego-
rized diagnoses from UDS as follows: DO; DO plus USI; USI
alone; and women with no demonstrable findings on UDS
were defined as normal UDS. In a similar fashion, subsequent
treatment data were categorized to be concordant with diag-
noses as follows:
1. BDO surgery^ for diagnosis including DO, percutaneous
t i b i a l n e r v e s t imu l a t i o n (PTNS ) o r s a c r a l
neuromodulation and/or botulinumA toxin injections into
the bladder.
2. BUSI surgery^ for diagnosis including USI, midurethral
sling including tension-free vaginal tapes (retropubic or
transobturator), fascial sling, bladder neck injection and
colposuspension.
3. BBladder relaxants^—antimuscarinics and Mirabegron
use were considered concordant with a UDS diagnosis
including DO or normal UDS
4. BNo treatment^ was considered concordant with a UDS
diagnosis of normal UDS
Other assumptions were that the effect of bladder relaxants
was assumed only at the time at which it was reported, where-
as the effect of surgery was assumed to be longer (i.e. those
reporting surgery at 6 months were presumed to still have had
surgery at 12 months). In addition, the women who reported
that they had had both surgery and bladder relaxants as a
proportion of those having surgery were in the minority
(15% at 6 months, 26% at 12 months). Surgery was assumed
to supersede the use of bladder relaxants, so to simplify the
analysis, this dual effect was ignored (i.e. for women catego-
rized as having USI or DO surgery, this may or may not
include the use of bladder relaxants).
The relationship between UDS diagnoses and subsequent
treatment was examined using a multinomial logistic
regression model [13] with the treatment group variable as
the outcome and UDS diagnosis as the explanatory variable.
The overall importance of this variable was determined using
Chi-squared test with results presented alongside estimates of
odds ratios (OR) and 95% confidence intervals (CI; the Bno
treatment^ group was used as the reference). Frequencies and
percentages are presented for the results of the PGI-I question
measured at 12 months, with means and standard deviations
presented for ICIQ-OAB scores (measured on a 0 [best] to 16
[worst] scale) after 6 and 12 months. Mean change from base-
line and 95% confidence intervals were calculated and paired t
tests were used to test statistical significance. Further analysis
was completed using logistic and linear repeated measures
regression models [14] to examine the effect of UDS diagno-
sis on the patient-reported outcome measures (PROMs) and
whether treatment was concordant with UDS diagnoses. The
statistical importance of these explanatory variables was de-
termined using Chi-squared and t tests. Comparative odds
ratios (OR) were calculated along with 95% CI using the
standard error (SE) taken from the respective models.
Results
The study recruited a total of 687 women, with a mean age of
52.7 years (SD 13.9) and an average body mass index of 30.6
(SD 12.2). Fifty-five percent of the women (387 out of 687)
were postmenopausal. According to clinical history, 61% (419
out of 687) had urgency-predominant MUI and 33% (226 out
of 687) reported urinary urgency along with increased fre-
quency. The median duration of symptoms was 3.0 years
(IQR: 1.6, 7.0). Out of 687 women recruited, 97% (666) had
complete UDS test results. On UDS, 43% (n = 284) were
diagnosed with DO alone, 17% (n = 115) had DO + USI,
14% (n = 92) were diagnosed with USI alone and 26%
(n = 175) had normal UDS. The questionnaire response rates
were 489 (71%) and 475 (69%), received at a median time of 7
and 20 months following testing (results are referred to below
as being at these times).
Effect of UDS on the management offered
Over the whole follow-up period, 63% of the women (292 out
of 467) reported that they had some form of condition-related
treatment; 70% of these treatments (205 out of 292) were
reported as bladder relaxants only, 20% USI surgery (57 out
of 292) and 10%DO surgery (30 out of 292; Table 1). Overall,
subsequent treatment was found to be highly associated with
diagnosis group (p < 0.0001); the odds of treatment for each
diagnosis (using the normal UDS diagnosis group as a refer-
ence) are given in Table 2.
Int Urogynecol J
Medium-term response in the entire cohort
Fifty-three percent of the women (248 out of 470) considered
their bladder problems to have improved (PGI-I responses) at
20 months. ICIQ scores also improved on average, reflecting
the declining severity of women’s symptoms (Table 3).
Medium-term responses by UDS diagnoses
The proportion of women indicating improvement on the
PGI-I question was higher in the USI (63%; 35 out of 56)
and DO + USI (58%; 48 out of 83) groups compared with
the DO (51%; 104 out of 205) and normal UDS (48%; 60 out
of 125) groups, although not enough to be statistically signif-
icant (p = 0.2). ICIQ scores were reduced from baseline in all
groups at both time-points (p < 0.001; Table 4, Fig. S1). There
was some evidence that ICIQ responses varied between diag-
nosis groups (p = 0.02); pairwise comparisons indicated that
the DO + USI group had a greater reduction than the DO
group (−1.1 points, 95% CI: −1.7, −0.4; p = 0.002) overall.
There were no statistically significant differences between the
other diagnosis groups.
Effect of receiving a medical or surgical treatment
concordant with a UDS diagnosis
At 20 months, 57% of women (168 out of 296) who had
received a treatment concordant with diagnosis felt that they
had improved, as opposed to only 45% (69 out of 152) in
those who had not (OR: 1.6, 95% CI 1.1 to 2.3; p = 0.02);
there was no overall evidence that this varied by UDS diag-
nosis (p = 0.1; Table 5). ICIQ scores were reduced at 7 and
20 months, regardless of whether the patient had had a con-
cordant treatment or not, although the scores were better in
those who did (−0.5, 95%CI: −0.9, −0.1; p = 0.02). There was
no evidence that the effect of receiving a concordant treatment
varied by UDS group (p = 0.3; Table S1).
Discussion
Main findings and interpretation
Urodynamics appears to influence treatment decisions made
by clinicians and patients in determining treatment pathways
in women presenting with OAB. Women with DO were three
times more likely to have had bladder relaxants than no treat-
ment than women with a normal diagnosis. This could be
interpreted as those who were shown to have DO either re-
ceived prescribed bladder relaxant tablets more or patient
compliance with taking the treatment was better. Women with
a diagnosis of DO plus USI were 15 times more likely to have
Table 1 Reported interventions
over the whole follow-up period
by UDS diagnosis: treatment
frequency indicated
Treatment
UDS
diagnosis
DO surgery (plus bladder
relaxants)
USI surgery (plus bladder
relaxants)
Bladder
relaxants only
No
treatment
Total
DO + USI 3 (3) 27 (11) 29 23 82
DO 19 (5) 6 (3) 119 57 201
USI 2 (0) 18 (6) 16 25 61
Normal
UDS
6 (1) 6 (1) 41 70 123
Total 30 57 205 175 467a
UDS urodynamics, DO detrusor overactivity, USI urodynamic stress incontinence
a 8 participants returned follow-up forms but did not complete treatment information
Table 2 Odds ratios (OR) of intervention versus no treatment over the
whole period using the normal UDS diagnosis group as a reference
Treatment
Diagnosis effect DO surgeryOR
(95%CI)
USI surgery
OR (95%CI)
Bladder relaxants
OR (95%CI)
DO vs normal
UDS
2.6 (1.2, 5.4) 1.0 (0.3, 2.7) 3.3 (2.4, 4.7)
DO + USI vs
normal UDS
0.8 (0.2, 2.8) 14.9 (6.6, 33.8) 2.0 (1.2, 3.2)
USI vs normal
UDS
1.0 (0.3, 3.2) 8.2 (3.5, 19.3) 1.1 (0.7, 1.9)
Table 3 International Consultation on Incontinence Questionnaire
(ICIQ) scores from baseline to 20 months
Mean (SD), n Change from baseline: mean, 95%CI, p value
Baseline 9.3 (2.7), 637
7 months 7.3 (3.3), 469 −1.9 (−2.2, −1.6), < 0.0001
20 months 7.0 (3.5), 460 −2.2 (−2.5, −1.9), < 0.0001
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USI surgery than no treatment, which may at least partly ex-
plain the improved ICIQ scores and PGI-I in this group com-
pared with the pure DO group.
A multicentre randomised double-blind trial (RCT) to deter-
mine whether women with or without a UDS finding of DO
responded differently to antimuscarinic treatment demonstrated
that UDS status was unable to predict treatment outcomes in
women treated with the antimuscarinic agents or placebo [11].
The objective in a recent Cochrane systematic review [15] was
to determine if treatment according to UDS-based diagnosis
compared with treatment based on history and examination
alone led to more effective clinical care and better clinical out-
comes in women with urinary incontinence. Two of the includ-
ed trials [16, 17] demonstrated that women who underwent
UDS were more likely to receive drugs to treat their symptoms
than who did not (45% vs 21%, RR 2.09, 95% CI 1.32–3.31).
Furthermore, three trials [18–20] found that those who had
UDS were more likely to have their management changed
(17% vs 3%, RR 5.07, 95% CI 1.87–13.74), although in five
trials [16–19, 21], it was found that women were not more
likely to undergo surgery after UDS (81% vs 79% RR 0.99,
95%CI 0.88–1.12). The evidence for the included surgical trials
was of moderate quality (based on GRADE outcomes).
Contrary to the findings of the Cochrane systematic review,
we found that more women with DO plus USI diagnosis had
received surgery by 20months’ follow-up compared with those
with a normal UDS diagnosis. Confirmation of the concurrent
pathophysiology of DO plus USImay have resulted in themore
clinicians offering USI surgery after suboptimal improvement
with bladder relaxants alone.
In the overall population at 20 months, just over half
the women (53%) reported long-term improvement in
symptoms and ICIQ scores were reduced from baseline
by 2.2 points (p < 0.001) on average, a difference that
appears to be clinically meaningful. However, women
treated with medical or surgical interventions based on
UDS diagnoses appear to have greater reductions in
symptoms than those who were not (57% vs 45%;
p = 0.02). ICIQ scores were reduced at both time points
regardless of whether the women received a treatment
concordant with UDS findings or not, although patients
receiving a concordant treatment reported a slightly great-
er reduction (−0.5 points; p = 0.02). The improvement
reported by those who did not receive a concordant treat-
ment could be for several reasons, such as the natural
fluctuation of the disease state, regression to the mean
and Hawthorne effect (individuals modify an aspect of
their behaviour as a response to their awareness of being
observed) [22]. The experience of UDS may have helped
women to understand their condition better and to im-
prove compl iance wi th l i fe s ty le measures and
medications.
Strengths and limitations
This study is one of the few reporting on the prospective
follow-up in women with urgency and urge-predominant
MUI and reporting better outcomes in the MUI group in
comparison to the DO group. The response rate for con-
tinued follow-up of the cohort was 69% at 20 months;
although not high, it is superior to other studies in the
field. We captured the opportunity to assess the prognostic
value of UDS and the outcomes following urodynamic
diagnoses. The patients were followed up for more than
12 months and validated questionnaires were used. We
believe that these data will hopefully offer some evidence
to the clinical community that UDS does change patient
management in current clinical practice.
Table 4 ICIQ scores by
diagnosis groups UDS diagnosis
DO + USI DO USI Nothing
Baseline mean (SD), n 9.8 (2.5) 9.8 (2.7) 8.9 (2.7) 8.2 (2.3)
7 months mean (SD), n 6.8 (3.5), 81 8.1 (3.4), 207 7.1 (3.3), 57 6.5 (2.8), 124
20 months mean (SD), n 6.6 (3.6), 82 7.7 (3.8), 199 6.2 (3.3), 55 6.5 (3.1), 123
Table 5 Proportion of patients
reporting improvement in
symptoms by UDS diagnosis and
whether a medical or surgical
treatment concordant with this
diagnosis had been received
UDS diagnosis Concordant medical
or surgical treatment = no (%)
Concordant medical
or surgical treatment = yes (%)
OR (95%CI)
DO + USI 8/25 (32) 39/55 (71) 5.2 (1.9, 14.4)
DO 36/79 (46) 63/118 (53) 1.4 (0.8, 2.4)
USI 24/41 (59) 10/14 (71) 1.8 (0.5, 6.6)
Normal UDS 1/7 (14) 56/109 (51) 6.3 (0.7, 54.4)
Total 69/152 (45) 168/296 (57)
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The major limitation of this study is that it is not a ran-
domized controlled trial (RCT) of outcomes based on treat-
ment given to those with or without DO. Our results are
therefore subject to unknown confounders, which may bias
our results, including decisions to treat being based on in-
formation from sources other than UDS. Also, we could
only ascertain whether women had Bever^ having taken
bladder relaxants as opposed to women currently taking
bladder relaxants. Second, the number of women having
both bladder relaxants and surgery was small, and therefore
could not be reliably distinguished from those who had sur-
gery alone. In addition, we did not collect data on therapies
such as supervised intensive pelvic floor muscle training,
bladder retraining, lifestyle changes etc., but we presumed
that the conservative treatment was already exhausted before
patients were referred for UDS. A further limitation was that
we did not link information on HRT use with urodynamic
diagnoses. Lack of oestrogen following the menopause is
known to cause atrophic changes, which may be associated
with lower urinary tract symptoms [23].
The response rate was 69%, in spite of sending re-
minder questionnaires, emails and telephone calls to im-
prove this yield. Although we have no reason to suspect
that patients with missing responses were any different
from those who responded to questionnaires we cannot
rule out that this may have affected our conclusions to
an unknown degree.
Conclusions
Urodynamics appears to influence treatment decisions
made by clinicians in determining treatment pathways in
women presenting with OAB. Women treated based on
UDS diagnoses appear to have greater reductions in
symptoms than those who do not. In women with OAB,
a multicentre RCT comparing patient outcomes of treat-
ment based on UDS diagnoses versus treatment based on
clinical assessment (history and examination alone) and
related health economic evaluation for these diagnostic
interventions is planned. This will help to consolidate
the role of UDS in the management of these women, as
has been done for stress urinary incontinence [24].
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